Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...
This Unpopular Dividend Stock Is a Buy
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
Should Bristol-Myers Squibb Company (NYSE:BMY) Be In Your Early Retirement Portfolio?
We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...
Bristol Myers Squibb Co. stock rises Monday, still underperforms market
Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock
Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...
First Hawaiian Bank Grows Stock Position in Bristol-Myers Squibb (NYSE:BMY)
First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.